Adalimumab

An anti-TNF biologic you inject under your skin at home with a pen or syringe.

Also called: humira, hyrimoz, imraldi, idacio, yuflyma, ada, adalimumib, adalimuab

Related words anti-tnf biosimilar therapeutic drug monitoring

Topics Biologics and newer medicines

Questions people ask

What is a biosimilar, and is it as good as the original brand?

A biosimilar is a version of a biologic medicine shown to have no meaningful differences in quality, safety or effectiveness from the original brand. For example, Remicade was the first infliximab and Remsima, Inflectra, Flixabi and Zessly are biosimilars; Humira was the first adalimumab and Amgevita, Hyrimoz, Imraldi, Idacio and Yuflyma are biosimilars. NHS England says switching between them is now accepted practice. A Cochrane review found infliximab and its CT-P13 biosimilar may work similarly.

Sources

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

Which biologics and targeted medicines are approved for Crohn's on the NHS?

NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.

Sources

Where to read more

Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature

Clinical Practice Case report Mar 2025 For professionals

Describes a 23-year-old woman with Crohn's who developed pyoderma gangrenosum and improved on adalimumab, alongside a review of similar published cases. The authors stress early diagnosis and joint care between specialists.

Topics Beyond the gut Biologics and newer medicines

Jargon explained pyoderma gangrenosum adalimumab

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

NICE Guideline May 2010 For professionals

NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease

Biosimilar medicines

NHS England Web page Patients and professionals

NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.

Topics Biologics and newer medicines Medicines

Jargon explained biosimilar originator medicine switching

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

Starting biologic medication

Royal Free London NHS Foundation Trust Leaflet Aug 2025 For patients

A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.

Topics Biologics and newer medicines

Jargon explained biologic infusion biosimilar

Search everything for "adalimumab"